Gopala Krishna leads Inotiv’s genetic toxicology offering. He brings 35 years of experience in large (Pfizer, Abbott Labs) and small (MGI, Enzon, Supernus) pharma as senior scientist, director, and VP leading nonclinical programs. He served as professor (adjunct) of pharmacology and toxicology at the University of Michigan, School of Public Health in Ann Arbor, MI. Most recently, Dr. Krishna was principal consultant at Paraxel as the subject matter expert, integrated product development, interfacing with global health authorities in the regulatory submissions and issue resolution.
His background and experience in genetic toxicology play a key role in assisting our clients with the development of safe novel therapeutics. He is president of the National Capital Area Chapter (NCAC) of Society of Toxicology (SOT) and has been a contributing senior member of the Environmental Mutagenesis and Genomics (Genetic Toxicology) Society (EMGS) for over 35 years.